Guggenheim analyst Brad Canino assumed coverage of Relay Therapeutics (RLAY) with a Buy rating and price target of $15, up from $10. The analyst names Relay a “best idea.” The firm has high conviction in the company’s breast cancer potential and says it could undergo a nearer-term turnaround for the recently initiated development of RLY-2608 for vascular malformations. The company’s mutant-selective inhibitor could deliver substantial cross-trial increases in efficacy based, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics assumed with a Buy at Guggenheim
- Relay Therapeutics price target lowered to $14 from $16 at H.C. Wainwright
- Relay Therapeutics price target lowered to $19 from $29 at Raymond James
- Relay Therapeutics Reports Q2 2025 Financial Results and Progress
- Relay Therapeutics reports Q2 EPS (41c), consensus (47c)